Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab

BACKGROUND: Durvalumab is an anti-PD-L1 immune checkpoint inhibitor approved for consolidation therapy for patients with stage III non-small cell lung cancer (NSCLC) after chemoradiation. The purpose of our study was to evaluate the association between the degree of tumor PD-L1 expression and outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazieh, Khalid, Gad, Mohamed, Saad, Anas, Wei, Wei, Pennell, Nathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350087/
https://www.ncbi.nlm.nih.gov/pubmed/34430348
http://dx.doi.org/10.21037/tlcr-21-249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350087/
https://www.ncbi.nlm.nih.gov/pubmed/34430348
http://dx.doi.org/10.21037/tlcr-21-249

Ejemplares similares